A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia

BJU International

Volumn 94, Issue 1, 2004, Pages 83-88

  Boyle, Peter ^a,f   Robertson, Christopher ^b,c   Vaughan, E Darracott ^d   Fitzpatrick, John M ^e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c Scottish Centre for Infection and Environmental Health   (United Kingdom)

^d Department of Obstetrics Gynecology   (United States)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

BPH; Efficacy; Flow rate; IPSS; Meta analysis; TUNA

Indexed keywords

ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FOLLOW UP; HUMAN; META ANALYSIS; MORBIDITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SEXUAL FUNCTION; SURGICAL TECHNIQUE; TRANSURETHRAL NEEDLE ABLATION; TREATMENT FAILURE; TREATMENT OUTCOME; URINE FLOW RATE; URODYNAMICS;

AGED; CATHETER ABLATION; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; URINARY RETENTION; URODYNAMICS;

EID: 3242815312     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04906.x     Document Type: Article

References (35)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
2. Boyle P, Robertson C, Mazzetta C, et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UREPIK study. BJU Int 2003; 92: 409-14
3. Boyle P, Maisonneuve P, Steg A. Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. J Urol 1996; 155: 176-80
4. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999; 83: 410-5
5. Walsh PC. Benign prostatic hyperplasia. In Walsh PC, Retik AS, Vaughn ED, Wein AJ eds. Campbell's Urology, 6th edn. Philadelphia: WB Saunders, 1992: 1007-27
6. Roehrborn CG, Bartsch G, Kirby R et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; 58: 642-50
7. Boyle P, Gould L, Roehrborn C. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride. A meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
8. Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434
9. Kirby RS, Altwein JE, Bartsch G et al. The efficacy and tolerability of doxazosin and finasteride, alone or in combination, in the treatment of symptomatic benign prostatic hyperplasia, results of the Prospective European Doxazosin And Combination Therapy (PREDICT) Trial. Urology 2003; 61: 119-26
10. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001; 58: 717-22
11. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of Permixon in the treatment of BPH. Urology 2000; 55: 533-9
12. Schulman CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD. Transurethral needle ablation (TUNA). Safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol 1993; 24: 415-23
13. Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate (TUNA). A new treatment of benign prostatic hyperplasia using interstitial radiofrequency energy. J Urol (Paris) 1995; 101: 33-6
14. Issa MM. Transurethral needle ablation of the prostate: report of initial US clinical trial. J Urol 1996; 156: 413-9
15. Bruskewitz R, Issa MM, Roehrborn C et al. A prospective, randomised one-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998; 159: 1588-94
16. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and the need of surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997; 49: 839-45
17. Hill B, Belville W, Bruskewitz R et al. Five year results of a prospective randomised trial comparing transurethral needle ablation (TUNA) to TURP for treatment of symptomatic BPH. AUA Annual Meeting Clinical Abstracts. Lippincott, Williams & Wilkins 2002
18. Chandrasekar P, Virdi JS. Transurethral needle ablation of the prostate (TUNA) - a prospective study, six year follow-up. AUA Annual Meeting Clinical Abstracts, Lippincott, Williams & Wilkins, 2001
19. Schatzl G, Madersbacher S, Djavan B, Lang T, Marberger M. Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options. Eur Urol 2000; 37: 695-701
20. Ramon J, Lynch TH, Eardley I et al. Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study. Br J Urol 1997; 80: 128-34
21. Kahn SA, Alphonse P, Tewari A, Narayan P. An open study on the efficacy and safety of transurethral needle ablation of the prostate in treating symptomatic benign prostatic hyperplasia: the University of Florida experience. J Urol 1998; 160: 1695-700
22. Namiki K, Shiozawa H, Tsuzuki M, Mamiya Y, Matsumoto T, Miki M. Efficacy of transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia. Int J Urol 1999; 6: 341-5
23. Naslund MJ, Benson RC, Cohen ES, Gutierrez-Aceves J, Issa MM. Transurethral needle ablation (TUNA) for BPH in patients with median lobe enlargement. Report of a prospective multi-centre study. AUA Annual Meeting Clinical Abstracts. Lippincott, Williams & Wilkins, 2000
24. Bergamaschi F, Manzo M, Autieri G, Corrada P, Campo B. Five years experience using transurethral needle ablation (TUNA) in 204 BPH patients. AUA Annual Meeting Clinical Abstracts. Lippincott, Williams & Wilkins, 2000
25. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44: 89-93
26. Apostolos A, George M, Dimitrios A, George D, Ioannis C. Long-term efficacy and safety of transurethral needle ablation of the prostate (TUNA) for bladder outlet obstruction of prostatic origin: five-year experience. Eur Urol 2002; 40 (Suppl 1): 129
27. Murai M, Tachibana M, Mike M, Shiozawa H, Hirao Y, Okajima E. Transurethral needle ablation of the prostate: an initial Japanese clinical trial. Int J Urol 2001; 8: 99-105
28. Rosario DJ, Woo H, Potts KL, Cutinha PE, Hastie KJ, Chapple CR. Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 1997; 80: 579-86
29. Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year follow-up. J Urol 1997; 158: 1834-8
30. Medtronic. Protocol no. 10807. Traitement de l'hypertrophie benigne de la prostate (HBP) par thermocoagulation au moyen d'aiguilles par voie trans-uretrale (TUNA). Statistical Report, 8th April, 2003
31. Stram DO. Meta analysis of published data using a linear mixed effects model. Biometrics 1996; 52: 536-43
32. Bryk AS, Raudenbush SW. Hierarchical Linear Models. London: Sage Publications, 1992
33. Woodhouse G, Rasbash J, Goldstein H et al. MLn Command Reference. Multilevel Models Project. London: Institute of Education, 1995
34. Naslund MJ. Cost-effectiveness of minimally invasive treatments and transurethral resection (TURP) in benign Prostatic Hyperplasia (BPH). AUA Annual Meeting Clinical Abstracts. Lippincott, Williams & Wilkins, 2001
35. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol 2003; 17: 103-7